A pharmacotherapeutic approach to the regulation of hyperinsulinemia and obesity.

J Triscari, A C Sullivan

Index: Int. J. Obes. 11 Suppl 3 , 43-51, (1987)

Full Text: HTML

Abstract

A selective inhibitor of thromboxane synthase, Ro 22-3581 has been shown to be a useful tool for investigating the relationship between hyperinsulinemia and obesity. These studies have established that the pharmacologic normalization of the hyperinsulinemia associated with elevated weights in genetically obese and diet-induced obese rats resulted in decreased weight gain or weight loss. This effect was shown to be reversible, partially independent of the suppression of food intake, dependent on a functional endocrine pancreas, and not diabetogenic. However, these studies have not established a cause and effect relationship between the inhibition of thromboxane synthase activity by Ro 22-3581 and its suppression of insulin secretion and circulating insulin levels.

Related Compounds

  • Ro 22-3581

Related Articles:

Suppression of urinary albumin excretion in diabetic rats by 4'(imidazol-1-yl) acetophenone, a selective inhibitor of thromboxane synthesis.

1990-10-01

[J. Lab. Clin. Med. 116(4) , 469-78, (1990)]

Thromboxane and pulmonary hypertension following E. coli endotoxin infusion in sheep: effect of an imidazole derivative.

1982-03-01

[Prostaglandins 23(3) , 273-85, (1982)]

Attenuation of the development of hypertension in spontaneously hypertensive rats by the thromboxane synthetase inhibitor, 4'-(imidazol-1-yl) acetophenone.

1982-08-01

[Prostaglandins 24(2) , 237-44, (1982)]

Selective inhibition of thromboxane synthesis in glycerol-induced acute renal failure.

1986-07-01

[Am. J. Kidney Dis. 8(1) , 26-30, (1986)]

More Articles...